Qbtech

Qbtech is a Swedish company founded in 2002 that specializes in technology solutions for Attention Deficit Hyperactivity Disorder (ADHD). The company is known for the QbTest, the first FDA-cleared objective test for ADHD evaluation and treatment monitoring. This test combines a computer-based task with motion capture technology to measure key ADHD symptoms—activity, attention, and impulsivity—in patients aged 6 to 60. The QbTest can be conducted in-clinic or remotely, providing flexibility for both clinicians and patients. Qbtech aims to bring objectivity and standardization to ADHD care, enhancing diagnostic accuracy and treatment monitoring. Their solutions are supported by over 40 independent studies, demonstrating improved access to care and enhanced clinician confidence. The company operates globally, with offices in Stockholm, Houston, and London, and serves healthcare providers and national health organizations in 13 countries. Qbtech has received multiple awards for its innovative contributions to mental health care, including the 2022 HSJ Partnership Award for Best Mental Health Partnership with the NHS.

• Employees 110
• Annual Revenue $7500000